bupivacaine/ neostigmine. — Competitive Intelligence Brief

bupivacaine/ neostigmine. (bupivacaine/ neostigmine.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic combination. Area: Anesthesia / Pain Management.

marketed Local anesthetic combination Voltage-gated sodium channels (bupivacaine); acetylcholinesterase (neostigmine) Anesthesia / Pain Management Small molecule

Target snapshot

bupivacaine/ neostigmine. (bupivacaine/ neostigmine.) — Ain Shams University. Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while neostigmine enhances and prolongs this effect by inhibiting acetylcholinesterase.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
bupivacaine/ neostigmine. TARGET	bupivacaine/ neostigmine.	Ain Shams University	marketed	Local anesthetic combination	Voltage-gated sodium channels (bupivacaine); acetylcholinesterase (neostigmine)
Lidocaine/Magnesium	Lidocaine/Magnesium	University of Wisconsin, Madison	marketed	Local anesthetic combination	Voltage-gated sodium channels; NMDA receptor
Normal saline, Lidocaine, dexmetomidine	Normal saline, Lidocaine, dexmetomidine	Kasr El Aini Hospital	marketed	Local anesthetic combination with sedative-analgesic agent	Voltage-gated sodium channels (lidocaine); alpha-2 adrenergic receptors (dexmedetomidine)
Lidocaine 7% + Tetracaine 7% cream	Lidocaine 7% + Tetracaine 7% cream	Galderma R&D	marketed	Local anesthetic combination	Voltage-gated sodium channels
Ropivacine and Chloroprocaine mixture	Ropivacine and Chloroprocaine mixture	University of New Mexico	marketed	Local anesthetic combination	Voltage-gated sodium channels
Synera patch for 12hrs/day	Synera patch for 12hrs/day	International Clinical Research Institute	marketed	Topical local anesthetic combination	Voltage-gated sodium channels
Lidocaine-chlorprocaine combination	Lidocaine-chlorprocaine combination	Hadassah Medical Organization	marketed	Local anesthetic combination	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic combination class)

1. University of Belgrade · 2 drugs in this class
2. Cedars-Sinai Medical Center · 1 drug in this class
3. Cutia Therapeutics（Wuxi）Co.,Ltd · 1 drug in this class
4. East Carolina University · 1 drug in this class
5. Galderma R&D · 1 drug in this class
6. Hadassah Medical Organization · 1 drug in this class
7. University of Alabama at Birmingham · 1 drug in this class
8. University of New Mexico · 1 drug in this class
9. Ain Shams University · 1 drug in this class
10. University of Wisconsin, Madison · 1 drug in this class